Secondary Breast Cancer in Hodgkin's Lymphoma Survivors

被引：15

作者：

Crump, Michael ^{[1
]}

Hodgson, David ^{[2
]}

机构：

[1] Univ Toronto, Princess Margaret Hosp, Div Hematol & Med Oncol, Toronto, ON, Canada

[2] Univ Toronto, Princess Margaret Hosp, Dept Radiat Oncol, Toronto, ON, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 26期

关键词：

INVOLVED-FIELD RADIOTHERAPY; RADIATION-THERAPY; 2ND MALIGNANCY; RISK-FACTORS; CYCLES; DISEASE; CHEMOTHERAPY; ABVD; TRIALS; NEOPLASMS;

D O I：

10.1200/JCO.2009.22.9120

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：4229 / 4231

页数：3

共 27 条

[1] Long-term cause-specific mortality of patients treated for Hodgkin's disease
Aleman, BMP
van den Belt-Dusebout, AW
Klokman, WJ
van't Veer, MB
Bartelink, H
van Leeuwen, FE
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) : 3431 - 3439
[2] Breast cancer and other second neoplasms after childhood Hodgkin's disease
Bhatia, S
Robison, LL
Oberlin, O
Greenberg, M
Bunin, G
FossatiBellani, F
Meadows, AT
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (12) : 745 - 751
[3] ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results
Bonadonna, G
Bonfante, V
Viviani, S
Di Russo, A
Villani, F
Valagussa, P
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 2835 - 2841
[4] Breast Cancer Risk in Female Survivors of Hodgkin's Lymphoma: Lower Risk After Smaller Radiation Volumes
De Bruin, Marie L.
Sparidans, Judith
van't Veer, Mars B.
Noordijk, Evert M.
Louwman, Marieke W. J.
Zijlstra, Josee M.
van den Berg, Hendrik
Russell, Nicola S.
Broeks, Annegien
Baaijens, Margreet H. A.
Aleman, Berthe M. P.
van Leeuwen, Flora E.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) : 4239 - 4246
[5] Dhani NC, 2007, BLOOD, V110, p499A
[6] Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years
Dores, GM
Metayer, C
Curtis, RE
Lynch, CF
Clarke, EA
Glimelius, B
Storm, H
Pukkala, E
van Leeuwen, FE
Holowaty, EJ
Andersson, M
Wiklund, T
Joensuu, T
van't Veer, MB
Stovall, M
Gospodarowicz, M
Travis, LB
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) : 3484 - 3494
[7] Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial
Duggan, DB
Petroni, GR
Johnson, JL
Glick, JH
Fisher, RI
Connors, JM
Canellos, GP
Peterson, BA
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) : 607 - 614
[8] Engert A, 2005, BLOOD, V106, p750A
[9] Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma:: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group
Engert, A
Schiller, P
Josting, A
Herrmann, R
Koch, P
Sieber, M
Boissevain, F
de Wit, M
Mezger, J
Dühmke, E
Willich, N
Müller, RP
Schmidt, BF
Renner, H
Müller-Hermelink, HK
Pfistner, B
Wolf, J
Hasenclever, D
Löffler, M
Diehl, V
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) : 3601 - 3608
[10] Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma:: Final results of the GHSG HD7 trial
Engert, Andreas
Franklin, Jeremy
Eich, Hans Theodor
Brillant, Corinne
Sehlen, Susanne
Cartoni, Claudio
Herrmann, Richard
Pfreundschuh, Michael
Sieber, Markus
Tesch, Hans
Franke, Astrid
Koch, Peter
de Wit, Maike
Paulus, Ursula
Hasenclever, Dirk
Loeffler, Markus
Mueller, Rolf-Peter
Mueller-Hermelink, Hans Konrad
Duehmke, Eckhart
Diehl, Volker
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3495 - 3502

← 1 2 3 →